|Bid||75.14 x 3100|
|Ask||82.00 x 800|
|Day's Range||74.66 - 75.47|
|52 Week Range||56.81 - 75.57|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||56.54|
|Earnings Date||Apr 16, 2019 - Apr 22, 2019|
|Forward Dividend & Yield||1.28 (1.71%)|
|1y Target Est||80.08|
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue and EPS growth trajectoryIn its fourth-quarter earnings press release, Abbott Laboratories (ABT) reported worldwide sales of $30.6 billion in fiscal 2018, a YoY
- Data presented at ATTD confirms previous analyses that higher rates of scanning with the FreeStyle Libre system are strongly associated with improved glucose control - Prolonged hypoglycemia reduced ...
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Margin guidanceIn the company’s fourth-quarter earnings conference call, Boston Scientific (BSX) has guided for an adjusted gross margin of 72%–73% for fiscal 2018,
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Expense projections for fiscal 2019 In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted SG&A (selling, general, and
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Earnings projections for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) has guided for adjusted EPS of $1.53–$1.58 for
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
How Boston Scientific and Abbott Laboratories Stack Up(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Boston Scientific (BSX) guided for YoY revenue growth of 7%–9%, YoY organic
ABBOTT PARK, Ill. and BAGSVÆRD, Denmark, Feb. 20, 2019 /PRNewswire/ -- Abbott (ABT) and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). The partnership reflects both companies′ commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens.
How Boston Scientific and Abbott Laboratories Stack UpStock price movementsOn February 15, Boston Scientific (BSX) closed at $40.01, 0.23% higher than its previous closing price, 52.30% higher than its 52-week low of $26.27, and 0.79% below its
ABBOTT PARK, Ill., Feb. 20, 2019 /PRNewswire/ -- Abbott (ABT) announced today it has received CE Mark for the world's most sensitive rapid diagnostic test for the detection of hepatitis B surface antigen, the Determine™ HBsAg 2 test for use with serum, plasma or whole blood.1,2,3 This highly sensitive, easy-to-use, rapid lateral flow test enables identification of those with the virus and facilitates linkage to care in every healthcare setting.
On a regular basis I make notes on all the stocks I've been trading. This allows me to stay focused on my overall thesis and to have a clear plan of action. I generally will have 50 or more names.
Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.
Abbott Laboratories NYSE:ABTView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ABT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $11.09 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. ABT credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.